Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine. Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.
Full Court Clarifies and Recalibrates the Obviousness Test for “Pre-Raising the Bar” Patents
Sandoz AG v Bayer Intellectual Property GmbH [2024] FCAFC 135 Date of decision: 23 October 2024 Body: Full Court of the Federal Court of...